Showing results (4101-4110 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|June 21, 2025
Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastomaCaroline Zerbib, Lucas Robinet, Soleakhena Ken, et al.
The Oncologist|June 23, 2025
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancerAlexis LeVee, Esther Peluso, Melissa G Lechner, et al.
The Oncologist|May 31, 2025
A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgeryRuth A White, Valeria Mezzano-Robinson, Qiongyu Shi, et al.
The Oncologist|February 21, 2024
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy ApproachesDivya Chukkalore, Kira MacDougall, Viraj Master, et al.
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
The Oncologist|March 25, 2024
Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate CancerWilliam J Phillips, Fred Saad, Jennifer Leigh, et al.
The Oncologist|March 13, 2024
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine CarcinomaBlake J McKinley, Tucker W Coston, Jason S Starr
The Oncologist|March 9, 2024
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerHongmeng Zhao, Dan Li, Qian Li, et al.
The Oncologist|July 3, 2024
Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée)Perrine Rousset, Charlée Nardin, Eve Maubec, et al.
The Oncologist|July 11, 2024
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II studyMin Jin, Hong-Li Liu, Jun Xue, et al.
Pageof 571